Key result
Pre-existing coronary artery disease in liver transplant recipients did not significantly increase the risk of 12-year all-cause mortality compared to patients without coronary artery disease (14.8% vs 14.7%, HR 1.20).
Why the study?
The extent of postoperative myocardial injury remains unclear in liver transplant patients with coronary artery disease.
Does a history of coronary artery disease affect postoperative myocardial injury and long-term survival in patients undergoing liver transplantation?
Cohort (n=3,220)
No
Does a history of coronary artery disease affect postoperative myocardial injury and long-term survival in patients undergoing liver transplantation?
Hazard Ratio: 1.2 (95% CI 0.95–1.51)
Absolute Event Rate: 14.8% vs 14.7%
p-value: p=0.128
Despite experiencing higher levels of postoperative myocardial injury, liver transplant patients with a history of treated CAD have comparable 30-day and 12-year survival to those without CAD.
Supports transplant evaluation in selected patients with treated CAD; leaves open optimal perioperative cardiac monitoring strategies.
BACKGROUND: Coronary artery disease (CAD) is increasing worldwide due to the aging population and cardiometabolic syndrome. However, the extent of postoperative myocardial injury, the most common cause of death during the 30 days after noncardiac surgery, remains unclear with respect to liver transplant (LT) patients with CAD. We examined the link between post-LT high sensitivity cardiac troponin I (hs_cTnI) and long-term survival according to liver disease severity. METHODS: Consecutive patients who underwent LT (n = 3,220) from 2010 to 2020 were evaluated retrospectively. CAD was defined as a history of coronary artery bypass surgery or percutaneous intervention, or previous myocardial infarction. Peak hs_cTnI levels within 30 days post-transplant were compared in patients with and without CAD. The primary endpoint was defined as an all-cause mortality at 12 years following LT. Secondary endpoints include peak hs_cTnI level within post-transplant 30 days and 30-day mortality. Survival analysis was performed using the Kaplan-Meier method. RESULTS: CAD patients (n = 264, 8.2%) had higher peak hs_cTnI levels within 30 days post-LT than those without CAD (median [interquartile]: 0.068 [0.030-0.154] vs. 0.087 [0.037-0.203] ng/ml, respectively; P = 0.004); however, the mortality rate was comparable (14.7% vs. 14.8%, respectively, P = 0.999), at 12 years, and 1.9% vs. 1.1% (P = 0.522) at 30 days, respectively, at 30 days. Subgroup analysis with stratified liver disease severity identified a similar risk of long-term mortality. CONCLUSIONS: Although the peak hs_cTnI level within 30 days was higher in revascularized or treated CAD patients after LT compared those without CAD, long-term mortality rates at 12 years and 30-day mortality rate were comparable.
No takes yet. Share an insight, caveat, or question.
Kwon et al. (2022) conducted a cohort in Liver transplant patients with coronary artery disease (n=3,220). Coronary artery disease vs. No coronary artery disease was evaluated on All-cause mortality at 12 years (HR 1.20, 95% CI 0.95-1.51, p=0.128). Pre-existing coronary artery disease in liver transplant recipients did not significantly increase the risk of 12-year all-cause mortality compared to patients without coronary artery disease (14.8% vs 14.7%, HR 1.20).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: